Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

11 Oct 2021

Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.

Mergers — Supernus adds to its CNS portfolio with $400m buyout of Adamas

Supernus Adds To CNS Portfolio, Especially In Parkinson’s, With Adamas Buyout

More from Deals

More from Business